MARKET

MGNX

MGNX

MacroGenics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

29.49
+0.61
+2.11%
After Hours: 29.49 0 0.00% 16:00 05/14 EDT
OPEN
29.23
PREV CLOSE
28.88
HIGH
29.65
LOW
28.57
VOLUME
632.57K
TURNOVER
--
52 WEEK HIGH
36.48
52 WEEK LOW
18.16
MARKET CAP
1.77B
P/E (TTM)
-11.6442
1D
5D
1M
3M
1Y
5Y
Integral Health Asset Management, LLC Buys Centene Corp, Danaher Corp, Intellia Therapeutics ...
GuruFocus News · 4d ago
Medulloblastoma Drug Market Size 2021: Industry Outlook, Present Scenario of Manufacturers, Growth Factors, Opportunities and Forecast to 2027
May 07, 2021 (The Expresswire) -- Global “Medulloblastoma Drug Market” report provides a detailed qualitative analysis of the Medulloblastoma Drug market...
The Express Wire · 05/07 08:20
Here's Why MacroGenics, Inc.'s (NASDAQ:MGNX) CEO Might See A Pay Rise Soon
Simply Wall St. · 05/07 06:55
Macrogenics Inc Shares Up 32.8% Since SmarTrend's Buy Recommendation (MGNX)
May 07, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for Macrogenics Inc (NASDAQ:MGNX) on February 26th, 2021 at $24.06. In...
marketwatch.com · 05/07 05:23
Evercore ISI Believes MacroGenics (MGNX) Won’t Stop Here
Evercore ISI analyst Jonathan Miller maintained a Buy rating on MacroGenics (MGNX) on April 30. The company's shares closed last Friday at $32.36, close
SmarterAnalyst · 05/03 07:26
--Credit Suisse Raises MacroGenics' PT to $39 from $37, Notes Continued Pipeline Progress; Keeps Outperform Rating
MT Newswires · 04/30 11:37
--SVB Leerink Adjusts MacroGenics PT to $40 From $37, Maintains Outperform Rating
MT Newswires · 04/30 08:49
--HC Wainwright Adjusts MacroGenics' Price Target to $41 From $36, Maintains Buy Rating
MT Newswires · 04/30 07:52
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MGNX. Analyze the recent business situations of MacroGenics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MGNX stock price target is 37.56 with a high estimate of 50.00 and a low estimate of 17.00.
EPS
Institutional Holdings
Institutions: 216
Institutional Holdings: 64.08M
% Owned: 106.74%
Shares Outstanding: 60.04M
TypeInstitutionsShares
Increased
64
5.30M
New
22
1.19M
Decreased
35
6.11M
Sold Out
14
493.19K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.85%
Pharmaceuticals & Medical Research
+1.14%
Key Executives
Non-Executive Chairman/Independent Director
Paulo Costa
President/Chief Executive Officer/Director
Scott Koenig
Chief Financial Officer/Senior Vice President/Secretary
James Karrels
Senior Vice President/Chief Scientific Officer
Ezio Bonvini
Senior Vice President
Stephen Eck
Senior Vice President
Eric Risser
Senior Vice President
Thomas Spitznagel
Vice President/General Counsel
Jeffrey Peters
Vice President/Controller/Treasurer
Lynn Cilinski
Independent Director
Karen Ferrante
Independent Director
Kenneth Galbraith
Independent Director
Edward Hurwitz
Independent Director
Scott Jackson
Independent Director
Federica O'Brien
Independent Director
Jay Siegel
Independent Director
David Stump
No Data
About MGNX
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.

Webull offers kinds of MacroGenics Inc stock information, including NASDAQ:MGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MGNX stock methods without spending real money on the virtual paper trading platform.